Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions

Medical University of Graz

Status: Completed

Conditions: Diabetes Mellitus, Type 1

Treatments: Device: Glucose Sensor

Study type: Interventional

Funder types: Other

Identifiers

NCT02614768

SPIDIMAN_01

Details and patient eligibility

About

The purpose of this study is to assess accuracy and reliability of the SPIDIMAN continuous glucose monitoring (CGM) sensor system with regard to values as measured by Super GL and compare these results with similar evaluations of the Medtronic MiniMed 640G system, the Abbott FreeStyle Libre Flash Sensor and the DexCom G4 Platinum Sensor in patients with type 1 Diabetes.

Full description

The study is a single-center open-label study in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) therapy. The study will include a total of 12 subjects.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent obtained after being advised of the nature of the study
• Male or female aged ≥18 years
• Type 1 diabetes for at least 6 months according to the World Health Organization (WHO) definition
• Treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) for at least 3 months
• Body Mass Index (BMI) < 35 kg/m²
• Willing and able to wear 5 CGM devices for the duration of the study and undergo all study procedures.
• HbA1c ≤ 86 mmol/mol

Exclusion criteria

• Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
• Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
• Any mental condition rendering the subject incapable of giving his consent
• Subject is using a medication that significantly impacts glucose metabolism (oral steroids) except if stable for at least the last three months and expected to remain stable for the study duration
• Subject may not use acetaminophen (paracetamol) while participating in the study
• Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study.
• Subject is actively enrolled in another clinical trial
• Known adrenal gland problem, pancreatic tumour, or insulinoma
• Inability of the subject to comply with all study procedures
• Inability of the subject to understand the patient information.
• Subject donated blood in the last 3 months

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Glucose Sensor

Experimental group

Description:

Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).

Treatment:

Device: Glucose Sensor